nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.10.2011 | General Gynecology

Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol–cyproterone acetate

verfasst von: Funda Gode, Cigdem Karagoz, Cemal Posaci, Bahadir Saatli, Didem Uysal, Mustafa Secil, Bahri Akdeniz

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to evaluate the alteration of cardiovascular and metabolic risk parameters of polycystic ovary syndrome (PCOS) patients after a 6-month treatment with an oral contraceptive (OC) containing cyproterone acetate (CPA).

Methods

Forty women with PCOS were evaluated at baseline and after treatment with an OC. Carotid intima-media thickness (CIMT), brachial artery flow-mediated dilatation (FMD), nitrate-mediated dilatation (NMD), high sensitive (hs)-CRP, lipid levels, index of glucose sensitivity, and homeostasis model assessment of insulin resistance index (HOMA) were assessed.

Results

Mean CIMT was significantly elevated (0.03 ± 0.01 mm) (p < 0.05). There was a tendency of reduction in FMD, which was significant among overweight patients (p < 0.05). Total cholesterol, low-density lipid (LDL), and triglyceride levels were significantly elevated (p < 0.05).

Conclusion

CIMT as an indicator of early atherosclerosis and FMD as a finding of endothelial dysfunction seem to be deteriorated especially in overweight PCOS patients who were prescribed to OC containing cyproterone acetate for 6 months.

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yıldız BO (2004) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745–2749PubMedCrossRef

ACOG Practice Bulletin (2009) Clinical management guidelines for obstetrician–gynecologists: polycystic ovary syndrome. Obstet Gynecol 114:936–949CrossRef

Mak W, Dokras A (2009) Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost 35(7):613–620PubMedCrossRef

Vrbikova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11:277–291PubMedCrossRef

Nader S, Diamanti-Kandarakis E (2007) Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 22:317–322PubMedCrossRef

Yildiz BO (2008) Oral contaceptives in polycystic ovary syndrome: risk-benefit assesment. Semin Reprod Med 26:111–120PubMedCrossRef

Baillargeon JP, McClish DK, Essah PA, Nestler JE (2005) Association between the current use of low-dose oral contraceptives and cadiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90:3863–3870PubMedCrossRef

Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115:459–467PubMedCrossRef

Juonala M, Viikari J, Laitinen T, Marniemi J, Helenius H, Ronnemaa T, Raitakari OT (2004) Interrelations between brachial endothelial function and carotid intima-media thickness in young adults. Circulation 110:2918–2923PubMedCrossRef

10.

Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z (2004) Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89:2160–2165PubMedCrossRef

11.

Lakhani K, Hardiman P, Seifalian AM (2004) Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 175:353–359PubMedCrossRef

12.

Orio F, Palomba S, Cascella T, Simone BD, Biase SD, Russo T, Labella D, Zullo F, Lombardi G, Colao A (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:4588–4593PubMedCrossRef

13.

Carmina E, Orio F, Palombo S, Longo R, Cascella T, Lombardi G, Rini GB, Lobo RA (2006) Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119:356.e 1–356.e 6CrossRef

14.

Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453–2455PubMedCrossRef

15.

Rotterdam ESHRE/ASRM-sponsored PCOS Concensus Workshop Group (2004) Revised 2003 concensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

16.

Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalance and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169PubMedCrossRef

17.

Birdsall MA, Farquhar CM, White HD (1997) Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catherization. Ann Intern Med 126:32–35PubMed

18.

Meyer C, McGrath BP, Teede HJ (2007) Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30:471–478PubMedCrossRef

19.

Battaglia C, Mancini F, Fabbri R, Persico N, Busacchi P, Facchinetti F, Venturoli S (2010) Polycystic ovary syndrome and cardiovascular risk in young patients treated with drosperinone–ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril 94(4):1417–1425PubMedCrossRef

20.

Luque-Ramirez ML, Mendieta-Azcona C, Alverez-Blasco F, Escobar-Morreale HF (2009) Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril 91:2527–2536PubMedCrossRef

21.

Mancini F, Cianciosi A, Persico N, Facchinetti F, Busacchi P, Battaglia C (2010) Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study. Am J Obstet Gynecol 202(2):169.e1–169.e8CrossRef

22.

Buchner NJ, Rump LC (2003) Oral contraceptives and endothelial function: harm or benefit? J Hypertens 21:2227–2230PubMedCrossRef

23.

Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C (2004) Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89:5592–5596PubMedCrossRef

24.

Virdis A, Pinto S, Versari D, Salvetti G, Bernini G, Fruzetti F, Genazzani AR, Taddei S, Salvetti A (2003) Effect of oral contraceptives on endothelial function in the peripheral microcirculation of healthy women. J Hypertens 21:2275–2280PubMedCrossRef

25.

Lizarelli PM, Martins WP, Vieira CS, Soares GM, Franceschini SA, Ferriani RA, Patta MC (2009) Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception 79:35–40PubMedCrossRef

26.

Vural B, Calıskan E, Turkoz E, Kilic T, Demirci A (2005) Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 20:2409–2413PubMedCrossRef

27.

Mancini F, Cianciosi A, Reggiani GM, Facchinetti F, Battaglia C, Aloysio D (2009) Endothelial function and its relation to leptin, homocysteine, and insulin resistance in normalweight and overweight eumenorrheic women and PCOS patients: a pilot study. Fertil Steril 91:2537–2544PubMedCrossRef

28.

Karasek D, Vaverkova H, Halenka M, Budikova M, Novoty D (2006) Brachial endothelial function in subjects with familial combined hyperlipidemiaand its relationships to carotid artery intima-media thickness. Int Angiol 25:418–426PubMed

29.

Johnson HM, Douglas PS, Srinivasan SR, Bond MG, Tang R, Li S, Chen W, Berenson GS, Stein JH (2007) Predictors of carotid intima media thickness progression in young adults: the Bogalusa Heart Study. Stroke 38:900–905PubMedCrossRef

30.

Diamanti-Kandarakis E, Kandarki E, Christakou C, Panidis D (2009) The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obes Rev 10:431–441PubMedCrossRef

31.

Soares GM, Vieira CS, Martin W, Dos Reis RM, de Sa MF, Ferriani RA (2009) Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int J Clin Pract 63:160–169PubMedCrossRef

32.

Culberg G, Hamberger L, Mattsson LA, Mobacken H, Samsioe G (1985) Lipid metabolic studies studies in women with a polycystic ovary syndrome during treatment with a low dose desogestrel–ethinyl estradiol combination. Acta Obstet Gynecol Scand 64:203–207CrossRef

33.

Korytkowski MT, Mokan M, Horwitz MJ, Sl Berga (1995) Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:3327–3334PubMedCrossRef

34.

Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A (2004) Drosperinone for the treatment hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89:2817–2823PubMedCrossRef

35.

Prelevic GM, Würzburger MI, Trpkovic D, Balint-Peric L (1990) Effects of a low dose estrogen–anti-androgen combination (Diana-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol Endocrinol 4:157–168PubMedCrossRef

36.

Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, Martinez–Bermejo E, Lasuncion MA, Escobar-Morreale HF (2007) Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 92:2453–2461PubMedCrossRef

37.

Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 17:1729–1737PubMedCrossRef

38.

Cauci S, Santolo MD, Culhane JF, Stel G, Gonano F, Guaschino S (2008) Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol 111:857–864PubMedCrossRef

39.

Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS (2008) The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 93:4299–4306PubMedCrossRef

40.

Buchbinder S, Kratzsch J, Fiedler GM, Yar V, Brügel M, Leichtle A, Weber W, Alexander H, Matthes G, Thiery J (2008) Body weight and oral contraceptives are the most important modulators of serum CRP levels. Scand J Clin Lab Invest 68:140–144PubMedCrossRef

41.

Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD (2001) Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103:1410–1415PubMed

42.

Soares GM, Vieira CS, Martins WP, Fraceschini SA, Reis RM, Silva de Sa MF, Ferriani RA (2009) Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? Clin Endocrinol 71:406–411CrossRef

43.

Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2007) Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 22:3197–3203PubMedCrossRef

44.

Meyer C, McGrath BP, Cameron J, Kostsopoulos D, Teede HJ (2005) Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 90:4630–4635PubMedCrossRef

45.

Deugarte CM, Bartolucci AA, Azziz R (2005) Prevalance of insulin resistance in the polycystic ovary syndrome using the homeostasis model assesment. Fertil Steril 83:1454–1460PubMedCrossRef

46.

Cibula D, Fanta M, Vrbikova J, Stanicka S, Dvorakova K, Hill M, Skhra J, Zivny J, Skrenkova J (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenemia, SHBG and lipids in PCOS patients. Hum Reprod 20:180–184PubMedCrossRef

Titel: Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol–cyproterone acetate
verfasst von: Funda Gode
Cigdem Karagoz
Cemal Posaci
Bahadir Saatli
Didem Uysal
Mustafa Secil
Bahri Akdeniz
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 4/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-010-1790-9

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum

Fetal loss associated with second trimester amniocentesis

A randomized trial of ovulation induction with two different doses of Letrozole in women with PCOS

3-D ultrasound imaging of a prenatally diagnosed Beckwith–Wiedemann syndrome